Presentation is loading. Please wait.

Presentation is loading. Please wait.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Published byFrancis Anderson Modified over 5 years ago

Similar presentations

Presentation on theme: "Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled."— Presentation transcript:

1 Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)  Phoebe Rich, MD, Melinda Gooderham, MD, Hervé Bachelez, MD, PhD, Joana Goncalves, MD, Robert M. Day, PhD, Rongdean Chen, PhD, Jeffrey Crowley, MD  Journal of the American Academy of Dermatology  Volume 74, Issue 1, Pages (January 2016) DOI: /j.jaad Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Study design of Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and ESTEEM 2 ∗Doses of apremilast were titrated during the first week of administration and at week 16, when placebo patients were switched to apremilast. Dosing was maintained from weeks 16 to 32 (maintenance phase, period B). §Treatment from weeks 32 to 52 (randomized treatment withdrawal phase, period C) was based on the initial treatment assignment and the Psoriasis Area and Severity Index (PASI) response at week 32 (PASI-75 for ESTEEM 1 and PASI-50 for ESTEEM 2). ‡Patients initially randomized to apremilast who achieved PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2) response at week 32 and were rerandomized to placebo were switched back to apremilast at time of loss of effect, defined as loss of PASI-75 (ESTEEM 1) or loss of 50% of the PASI improvement obtained at week 32 (ESTEEM 2), but no later than week 52. ||Patients who did not achieve a PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2) response at week 32 were able to add topicals and/or ultraviolet (UV) B therapy at week 32 at the discretion of the investigator. Blinding was maintained until all patients discontinued or completed their week 52 visit. BID, Twice daily. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 For patients with nail psoriasis at baseline, mean percent change from baseline in target Nail Psoriasis Severity Index (NAPSI) score at week 16 (placebo-controlled phase, period A) and week 32 (maintenance phase, period B) in Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 (A) and ESTEEM 2 (B), and mean percent change in target nail NAPSI score by Psoriasis Area and Severity Index (PASI) response at week 16 (period A) in patients treated with apremilast 30 mg twice daily (BID) in ESTEEM 1 and ESTEEM 2 (C). Missing values at week 16 were imputed using the last observation carried forward (LOCF) methodology. Patients without an observation at week 32 were considered nonresponders. *P < .0001 versus placebo in ESTEEM 1 and *P = .0052 vs placebo in ESTEEM 2, both based on the χ2 test. PASI-50, ≥ 50% reduction from baseline in PASI score; PASI-75, ≥ 75% reduction from baseline in PASI score; PASI-90, ≥ 90% reduction from baseline in PASI score. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Percentage of patients with moderate to very severe scalp psoriasis at baseline (Scalp Physician Global Assessment [ScPGA] score ≥3) achieving ScPGA score of 0 or 1 at week 16 in Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and ESTEEM 2. Missing values at week 16 were imputed using the last observation carried forward methodology. *P < .0001 versus placebo, based on the χ2 test. BID, Twice daily. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Effect of apremilast 30 mg twice daily in a patient with scalp psoriasis at baseline (Scalp Physician Global Assessment [ScPGA] score = 5) (A) and week 16 (ScPGA score = 0) (B). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

6 Fig 5 Mean percent change from baseline in Nail Psoriasis Severity Index (NAPSI) score over 52 weeks in patients with nail psoriasis (NAPSI score ≥1) at baseline and Psoriasis Area and Severity Index response at week 32 in Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 (A) and ESTEEM 2 (B). BID, Twice daily. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.

A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.
Clinical evaluation of recombinant human platelet – derived growth factor for the treatment of lower extremity diabetic ulcers  David L. Steed, MD, the.

Clinical evaluation of recombinant human platelet – derived growth factor for the treatment of lower extremity diabetic ulcers  David L. Steed, MD, the.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.
Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients  Patrizia Weber, MD, S. Morteza Seyed Jafari,

Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients  Patrizia Weber, MD, S. Morteza Seyed Jafari,
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Remission and time of resolution of nail psoriasis during infliximab therapy  Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti,

Remission and time of resolution of nail psoriasis during infliximab therapy  Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti,
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Similar presentations

Ads by Google